Home
The Independent Research Enabler
  Read more
  • About us
  • Research Program
  • Partners
  • Projects
  • Results
  • Training
  • News
  • Contact
login
 

News Archive

Research Results

Beating the ‘Hospital Bacterium' MRSA
The Antistaph Project
Jointly Fighting Neglected Diseases
Phosphodiestherase Inhibitors
Safe Morphine Dosage Regimen for Newborns
Mechanism–based PK-PD Modeling Platform
Fundament for a Start-up: BioNovion
TNF Ligands in Cancer
Improving Healthcare Research by Using Coupled Data
Mondriaan Project

News

  • News list
  • Calendar
  • Newsroom (archive)
  • Newsletter (archive)
  • Newsletter subscription
  • Annual Reports
  • ISRC Reports
  • 27 February 2007 Contract signed

    In searching for novel schizophrenia susceptibility genes and drug targets,two Dutch universities,...

     Read more
     

Browse by date

    2013
  • March: 3 items
  • February: 1 item
  • January: 4 items
    • 2012
  • December: 5 items
  • November: 3 items
  • October: 1 item
  • September: 3 items
  • August: 2 items
  • July: 3 items
  • June: 3 items
  • May: 5 items
  • April: 2 items
  • February: 1 item
  • January: 2 items
    • 2011
  • December: 2 items
  • November: 3 items
  • October: 3 items
  • September: 2 items
  • August: 1 item
  • July: 3 items
  • June: 2 items
  • April: 2 items
  • March: 4 items
  • February: 2 items
  • January: 1 item
    • 2010
  • December: 1 item
  • November: 2 items
  • October: 7 items
  • September: 6 items
  • July: 3 items
  • June: 4 items
  • April: 5 items
  • February: 4 items
  • January: 6 items
    • 2009
  • December: 1 item
  • November: 1 item
  • October: 4 items
  • September: 3 items
  • August: 1 item
  • July: 5 items
  • April: 2 items
  • March: 2 items
  • February: 1 item
    • 2008
  • January: 1 item
    • 2007
  • December: 1 item
  • November: 1 item
  • April: 1 item
  • February: 1 item
    • 2006
  • December: 1 item
Share this page: 

TI Pharma
Galileiweg 8
2333 BD Leiden
Netherlands
Route

Call +31 71 332 2030 
Fax +31 71 332 2031 
Contact

  • email
  • linkedin 


© 2012 TI Pharma

About TI Pharma

Our Vision
Our Mission
Independent Research Enabler
Effective Research Management
Our Organization
Careers
The Dutch Landscape

Pharmaceutical Research Results

Safe Morphine Dosage Regimen for Newborns
Jointly Fighting Neglected Diseases
Fundament for a Start-up: BioNovion
Beating the 'Hospital Bacterium' MRSA
Improving Healthcare Research by Using Coupled Data

Pharmaceutical Research Partners    

Managing Public-Private Partnerships
Industry & Academic Partners 

Pharmaceutical Research Projects 

(Auto-) Immune Diseases Research
Brain Diseases Research
Cardiovascular Diseases Research
Cancer Research
Infectious Diseases Research
... Show all projects

Enabling Research Technologies

Lead Selection and in Silico Modeling 
Drug Formulation, Delivery and Targeting
... Show all projects

  • Our Vision
  • Our Mission
  • Independent Research Enabler
  • Effective Pharma Research Management
  • Our Organization
  • Careers
  • The Dutch landscape
  • Priority Medicines
  • Neglected Diseases
  • Social Medicines
  • Prizes & Awards
  • PhD Theses
  • SME Call 2012
  • Public-Private Partnerships
  • Consortium Partners
  • Safe Morphine Dosage Regimen for Newborns
  • Jointly Fighting Neglected Diseases
  • Fundament for a Start-up: BioNovion
  • Beating the 'Hospital' Bacterium MRSA
  • Improving Healthcare Research by Using Coupled Data
  • Biologicals
  • SafeSciMET
  • Business and Entrepreneurial Skills Training (BES)
  • Drug Discovery Simulation (DDIS)
  • Drug Development Simulation (DDES)
  • Intellectual Property (IP)
  • Project Management (PM)
  • Industry Day
  • Course Catalogue
  • News list
  • Calendar
  • Newsroom (archive)
  • Newsletter (archive)
  • Newsletter subscription
  • Annual Reports
  • ISRC Reports
  • (Auto-) Immune Diseases
    • CXC Chemokine Receptors
    • Insulin Resistance
    • COPD and Smoking
    • Systemic Inflammation
    • Osteoarthritis
    • Immune Modulation
    • Neuromodulation
    • Atopic Dermatitis (VCC)
    • OA all the way (SPC)
  • Cardiovascular Diseases
    • Drug-induced Weight Alteration
    • Metalloproteases
    • Nuclear Receptors as Targets
    • Renin Blockade
    • CXE1 as treatment for CVD (SPC)
  • Cancer
    • Novel Kinases
    • Kinases in Cancer
    • Signal Transduction Pathways
    • Nuclear Receptors in Cancer
    • Drug Responses in Breast Cancer
    • TNF Ligands in Cancer
    • miRNA Based Therapeutics
    • Applied Breast Cancer Diagnostics (VCC)
    • Kinases in Cancer 2 (VCC)
    • Antibodies for Cancer (VCC)
    • A new angle to breast cancer drug development (SPC)
    • Off-the-shelf antigen-loaded dendritic cell vaccines (SPC)
  • Infectious Diseases
    • Monitoring Leishmania, Tuberculosis and Trachoma
    • Malaria
    • Efficient Eradication
    • Effective HIV Therapy
    • MRSA
    • Respiratory Viruses
    • Vaccine against Chikungunya
    • Phosphodiesterase
    • Multidrug-resistant Bacterial Pathogens (VCC)
    • Schistosomiasis Treatment for Preschool Children
    • Malaria Vaccine (VCC)
    • IPAD (SPC)
    • Novel antimalarials (SPC)
  • Brain Diseases
    • Nanoscience and the BBB
    • Role of the Endocannabinoid System
    • Measuring Pain
    • Drugs for Psychiatric Disorders
    • Parkinson and Alzheimer Disease
    • Psychosis Susceptibility
    • CNS Drug Target Validation
  • Drug Discovery, Development and Utilisation
    • The Mondriaan Project
    • The Escher Project
    • Orphan Drugs Registry
    • Predictive Value of Animal Testing
    • Linking Healthcare Data (VCC)
    • Multiple Parameter Risk Response Score (VCC)
    • The HAMLET study (VCC)
    • Improving Access to the DDRMD (VCC)
    • Non Biological Complex Drugs Working Group
  • Target Finding, Validation, and Animal Models
    • Toll-like Receptors
    • GPCR Forum
    • Target Residence Time
    • Profiling of IL-17 modulators (SPC)
  • Lead Selection and in silico Modeling
    • Cardiotoxicity
    • Metabolic Stability
    • Ligand-Gated Ion Channel
    • PK-PD Modeling Platform
    • PK-PD Modeling Platform 2
  • Predictive Drug Disposition and Toxicology Research
    • Safety Biomarkers/ADR
  • Biomarkers and Bio-sensoring
    • CSF Proteome/Metabolome
    • Acetylation drug test (SPC)
    • IMMUNOCOLOURS (SPC)
  • Drug Formulation, Delivery and Targeting
    • Vaccine Delivery
    • Lipid Based Drug Delivery
    • The ProGraft Study (JC)
    • Sustained Ocular Drug Release
    • Nasal RSV vaccine (SPC)
  • Pharmaceutical Production Technologies
    • Hot Medicines / Oxytocin
    • Design Quality